Conventional chemotherapeutics have been developed into clinically useful agents based
on their ability to preferentially kill malignant cells, generally owing to their elevated …

The cyclin-dependent kinase (CDK)–RB–E2F axis forms the core transcriptional machinery
driving cell cycle progression, dictating the timing and fidelity of genome replication and …

In this review, we discuss the use of oncolytic viruses in cancer immunotherapy treatments in
general, with a particular focus on adenoviruses. These serve as a model to elucidate how …

The immunogenicity of malignant cells has recently been acknowledged as a critical
determinant of efficacy in cancer therapy. Thus, besides developing direct …

Leveraging the immune system to thwart cancer is not a novel strategy and has been
explored via cancer vaccines and use of immunomodulators like interferons. However, it …

Immunotherapy has moved to the forefront of modern oncologic treatment in the past few
decades. Various forms of immunotherapy currently are emerging, including oncolytic …

Oncolytic viruses (OVs), viruses that specifically result in killing tumor cells, represent a
promising class of cancer therapy. Recently, the focus in the OV therapy field has shifted …

Gene therapy has changed dramatically in the 28 years since the first human gene transfer
experiment in 1989. Alipogene tiparvovec, GlyberaR R, a recombinant adenoassociated …

Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disorder
clinically characterized by cognitive impairment, abnormal behavior, and social deficits …

We have conducted a phase 1 study of intravenous vvDD, a Western Reserve strain
oncolytic vaccinia virus, on 11 patients with standard treatment-refractory advanced …